This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott Presents Positive Study Results for Tendyne Device
by Zacks Equity Research
Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.
Veeva Systems (VEEV) Beats Q1 Earnings Estimates, Raises View
by Zacks Equity Research
Solid performance in Subscription revenues is a key catalyst for Veeva Systems (VEEV) in Q1.
Intuitive Surgical (ISRG) Gains on Strength in Robotics
by Zacks Equity Research
Higher adoption of Intuitive Surgical's (ISRG) robot-based da Vinci system and increasing procedure volumes are key catalysts at the moment.
Myriad Genetics' Prolaris Expands on New Coverage Decisions
by Zacks Equity Research
This increased rate in commercial insurer coverage for Myriad Genetics' (MYGN) Prolaris comes close on the heels of the NCCN guidelines.
McKesson (MCK) Q4 Earnings Miss, International Sales Rise
by Zacks Equity Research
McKesson (MCK) posts strong segmental performance and issues encouraging guidance for fiscal 2019.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Boston Scientific's (BSX) inorganic expansion plan bodes well for operational growth.
Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing
by Zacks Equity Research
Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.
Medtronic (MDT) Q4 Earnings: Can Spine Division Turn Around?
by Zacks Equity Research
Medtronic (MDT) expects to demonstrate positive outcome related to its distribution relationship with Mazor Robotics.
Zimmer Biomet New System Gets FDA Nod, to Boost Spine Wing
by Zacks Equity Research
Zimmer Biomet (ZBH) receives FDA's approval for the new system, which is likely to augment the company's lumbar spacers portfolio.
Cardiovascular Systems Rides on New Products Amid Tight Race
by Zacks Equity Research
Cardiovascular Systems (CSII) gains traction from a strong third-quarter fiscal 2018, witnessing a year-over-year revenue rise at both CAD and PAD businesses.
Will Solid Diabetes Arm Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is poised to gain on strength in Diabetes business in Q4 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.
ResMed Releases Positive U.S. & U.K. Study Data on COPD
by Zacks Equity Research
ResMed (RMD) presents the company-sponsored health economic studies, Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV), at the ATS 2018 International Conference.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) gains ground on product launches and international prospects.
Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is poised to gain on continued strength in RTG business in Q4.
Varian Medical (VAR) Merges With Brazil MOH to Fight Cancer
by Zacks Equity Research
Varian Medical (VAR) opts to spread radiotherapy accessibility in Latin America through Brazil MOH, other international ventures of the company hold promise.
Here's Why You Should Steer Clear of Cerner (CERN) for Now
by Zacks Equity Research
Cerner's (CERN) downbeat view for 2018 and soft Q1 results fail to cheer investors.
Here's Why You Should Sell DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
A rapidly changing healthcare environment in the United States, sluggish first quarter, declining margins and foreign exchange headwinds continue to hurt DENTSPLY SIRONA (XRAY).
QIAGEN (QGEN) Banks on Test Menu Expansion, Competition Stiff
by Zacks Equity Research
QIAGEN's (QGEN) top line continues to gain on expanding test menu amid stiff competition and declining HPV sales.
Medtronic Initiates Study on DES for Expanded Use in the US
by Zacks Equity Research
Medtronic (MDT) focuses on boosting CSH segment. Notably, successful results from The Bifurcation Cohort study will help the company to achieve expanded FDA approval for the Resolute Onyx DES.
Intuitive Surgical (ISRG) Up 4.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Illumina Takes Over Edico Genome, Fortifies NGS Platform
by Zacks Equity Research
Illumina (ILMN) proceeds with deals to boost NGS platform.
BioScrip's Core Business Strong Despite Reimbursement Issues
by Zacks Equity Research
BioScrip (BIOS) consistently advances with its multi-faceted CORE plan to perk up the money matters. However, reimbursement cuts pertaining to 21st century Cures Act might hinder growth in 2018.
Mellanox Technologies, MGM Resorts International, BP, Texas Instruments and Intuitive Surgical highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Mellanox Technologies, MGM Resorts International, BP, Texas Instruments and Intuitive Surgical highlighted as Zacks Bull and Bear of the Day
GNC Holdings' Global Prospects Solid, Competition Stiff
by Zacks Equity Research
GNC Holdings (GNC) progresses with deals to boost international presence.
CryoLife (CRY) Stock Gains 9.5% on Impressive Q1 Earnings
by Zacks Equity Research
CryoLife's (CRY) shares gain on growth in all product lines along with strong performance in all geographies in Q1.